Levobunolol and Betaxolol
| Autor: | Cheryl Y. Eto, Richard G. Bowe, Daniel A. Long, Robert J. Masi, Arthur Charap, Gary D. Novack, Deborah W. Alexander, Mark J. Weiss, Raymond S. Mullen, Gordon E. Johns, David L. Epstein |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
medicine.medical_specialty
Intraocular pressure genetic structures business.industry Eye disease Levobunolol Glaucoma Ocular hypertension medicine.disease eye diseases Betaxolol law.invention Clinical trial Ophthalmology Randomized controlled trial law Anesthesia medicine sense organs business medicine.drug |
| Zdroj: | Ophthalmology. 95:735-741 |
| ISSN: | 0161-6420 |
| Popis: | In a double-masked, randomized, controlled clinical trial, the authors evaluated the ocular hypotensive efficacy of twice-daily treatment with levobunolol (0.25 and 0.5%) and betaxolol (0.5%) in 85 patients with open-angle glaucoma or ocular hypertension. During the 3-month study, intraocular pressure (IOP) reductions in the two levobunolol groups were significantly greater than in the betaxolol group. From a mean baseline IOP of approximately 25 mmHg, overall mean reductions were 6.2 and 6.0 mmHg for the 0.25 and 0.5% levobunolol groups, respectively, and 3.7 mmHg for the betaxolol group. No clinically or statistically significant among-group differences were noted in the systemic safety variables evaluated. These data suggest that although all three treatments are effective, levobunolol provides a greater reduction in IOP than betaxolol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|